The Clinical Application of Suzetrigine - PubMed
6 days ago
- #Nav1.8 inhibitor
- #analgesia
- #acute pain
- Suzetrigine is a new highly selective Nav1.8 inhibitor for treating moderate to severe acute pain in adults.
- It acts by inhibiting the Nav1.8 channel and has a pharmacokinetic profile with Cmax of 0.62 μg/mL, Tmax of 3h, and effective t1/2 of 23.6h.
- Dosage is 100 mg first dose, followed by 50 mg orally every 12 hours.
- Clinical trials showed superior pain relief compared to placebo and fewer adverse reactions than hydrocodone bitartrate/acetaminophen.
- Common adverse events include itching, muscle spasms, increased creatine phosphokinase, rash, nausea, and vomiting.
- Suzetrigine is a CYP3A inducer, requiring caution with CYP3A substrates and dosage adjustments for hepatic or renal impairment.
- Further research is needed for its use in other pain types, special populations, and potential gender metabolic differences.